04/08/2026
When your lipid panel comes back…
LDL elevated.
Triglycerides climbing.
ApoB concerning.
Your doctor may prescribe a statin.
Three months later do you experience?
Muscle pain. Fatigue. Brain fog.
Most will stop taking it.
Sound familiar?
It should.
Statin non-compliance remains one of the biggest challenges in cardiovascular care. And even among those who stay on therapy, side effects often come at the cost of quality of life.
What if we approached this differently?
Introducing Sytrinol LNA — a multi-pathway strategy designed to support lipid optimization without the common trade-offs.
Three mechanisms. One goal: better cardiovascular outcomes.
✔️ Leucine (1.1g precision dosing)
Activates SIRT1 → improves metabolic flexibility, insulin sensitivity, and supports mitochondrial performance.
✔️ Low-dose Nicotinic Acid
Reduces triglyceride synthesis and VLDL production while enhancing fat oxidation — without the flushing and GI issues.
✔️ Polymethoxylated Flavones + Tocotrienols
Support LDL and triglyceride reduction via HMG-CoA reductase modulation — without muscle pain, cognitive effects, or CoQ10 depletion.
Why this matters: ApoB
ApoB is one of the most accurate predictors of cardiovascular risk.
Sytrinol LNA targets ApoB through multiple pathways simultaneously.
At the recent CALM 2026 conference, insights from Dr. James Min and Cleerly Health showed us that cardiovascular disease can be detected years before symptoms.
The real question becomes:
👉 Once you identify risk that early… what’s your plan?
For many in longevity medicine, Sytrinol LNA is becoming foundational.
Because managing risk shouldn’t come at the cost of how your patients feel.
👉 Ready to take a proactive approach to your heart health? Schedule your Discovery Call with The Wellness Firm today and let’s build your personalized longevity plan.
